NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Receives Average Recommendation of “Moderate Buy” from Analysts

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) has earned an average rating of “Moderate Buy” from the five ratings firms that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, two have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $8.50.

A number of research analysts have recently commented on NRSN shares. Roth Mkm started coverage on NeuroSense Therapeutics in a report on Tuesday, March 10th. They issued a “buy” rating and a $3.00 price objective on the stock. D. Boral Capital reiterated a “buy” rating and issued a $14.00 price objective on shares of NeuroSense Therapeutics in a report on Wednesday, April 8th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of NeuroSense Therapeutics in a report on Friday, May 8th.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Two Sigma Investments LP purchased a new position in shares of NeuroSense Therapeutics in the 3rd quarter valued at about $26,000. Jane Street Group LLC purchased a new position in shares of NeuroSense Therapeutics in the 2nd quarter valued at about $54,000. Yorkville Advisors Global LP purchased a new position in shares of NeuroSense Therapeutics in the 4th quarter valued at about $77,000. Finally, Squarepoint Ops LLC increased its holdings in shares of NeuroSense Therapeutics by 91.0% in the 3rd quarter. Squarepoint Ops LLC now owns 95,375 shares of the company’s stock valued at $119,000 after acquiring an additional 45,450 shares during the last quarter. Hedge funds and other institutional investors own 1.04% of the company’s stock.

NeuroSense Therapeutics Price Performance

Shares of NASDAQ NRSN opened at $0.82 on Friday. The stock’s 50-day moving average is $0.78 and its two-hundred day moving average is $0.89. NeuroSense Therapeutics has a 1-year low of $0.63 and a 1-year high of $2.60. The company has a market cap of $26.70 million, a price-to-earnings ratio of -1.52 and a beta of 1.60.

About NeuroSense Therapeutics

NeuroSense Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative and age-related neurological disorders. The company’s primary mission is to address unmet medical needs in diseases characterized by protein aggregation, chronic inflammation and cellular senescence in the central nervous system.

At the core of NeuroSense’s approach is a proprietary senotherapeutic platform designed to selectively target and clear senescent cells that contribute to neurodegeneration.